Publications

Detailed Information

Dosage, Intensity, and Frequency of Language Therapy for Aphasia: A Systematic Review-Based, Individual Participant Data Network Meta-Analysis

Cited 37 time in Web of Science Cited 44 time in Scopus
Authors

Brady, Marian C.; Ali, Myzoon; VandenBerg, Kathryn; Williams, Linda J.; Williams, Louise R.; Abo, Masahiro; Becker, Frank; Bowen, Audrey; Branden-burg, Caitlin; Breitenstein, Caterina; Bruehl, Stefanie; Copland, David A.; Cranfill, Tamara B.; Di Pietro-Bachmann, Marie; Enderby, Pamela; Fillingham, Joanne; Galli, Federica Lucia; Gandolfi, Marialuisa; Glize, Bertrand; Godecke, Erin; Hawkins, Neil; Hilari, Katerina; Hinckley, Jacqueline; Horton, Simon; Howard, David; Jaecks, Petra; Jefferies, Elizabeth; Jesus, Luis M. T.; Kambanaros, Maria; Kang, Eun Kyoung; Khedr, Eman M.; Kong, Anthony Pak-Hin; Kukkonen, Tarja; Laganaro, Marina; Ralph, Matthew A. Lambon; Laska, Ann Charlotte; Leemann, Beatrice; Leff, Alexander P.; Lima, Roxele R.; Lorenz, Antje; MacWhinney, Brian; Marshall, Rebecca Shisler; Mattioli, Flavia; MaviS, ilknur; Meinzer, Marcus; Nilipour, Reza; Noe, Enrique; Paik, Nam-Jong; Palmer, Rebecca; Papathanasiou, Ilias; Patricio, Brigida; Martins, Isabel Pavao; Price, Cathy; Jakovac, Tatjana Prizl; Rochon, Elizabeth; Rose, Miranda L.; Rosso, Charlotte; Rubi-Fessen, Ilona; Ruiter, Marina B.; Snell, Claerwen; Stahl, Benjamin; Szaf-larski, Jerzy P.; Thomas, Shirley A.; Van de Sandt-Koenderman, Mieke; van der Meulen, Ineke; Visch-Brink, Evy; Worrall, Linda; Wright, Heather Harris

Issue Date
2022-03
Publisher
Lippincott Williams & Wilkins Ltd.
Citation
Stroke, Vol.29 No.2, pp.956-967
Abstract
BACKGROUND AND PURPOSE: Optimizing speech and language therapy (SLT) regimens for maximal aphasia recovery is a clinical research priority. We examined associations between SLT intensity (hours/week), dosage (total hours), frequency (days/week), duration (weeks), delivery (face to face, computer supported, individual tailoring, and home practice), content, and language outcomes for people with aphasia. METHODS: Databases including MEDLINE and Embase were searched (inception to September 2015). Published, unpublished, and emerging trials including SLT and >= 10 individual participant data on aphasia, language outcomes, and time post-onset were selected. Patient-level data on stroke, language, SLT, and trial risk of bias were independently extracted. Outcome measurement scores were standardized. A statistical inferencing, one-stage, random effects, network meta-analysis approach filtered individual participant data into an optimal model examining SLT regimen for overall language, auditory comprehension, naming, and functional communication pre-post intervention gains, adjusting for a priori-defined covariates (age, sex, time poststroke, and baseline aphasia severity), reporting estimates of mean change scores (95% CI). RESULTS: Data from 959 individual participant data (25 trials) were included. Greatest gains in overall language and comprehension were associated with >20 to 50 hours SLT dosage (18.37 [10.58-26.16] Western Aphasia Battery-Aphasia Quotient; 5.23 [1.51-8.95] Aachen Aphasia Test-Token Test). Greatest clinical overall language, functional communication, and comprehension gains were associated with 2 to 4 and 9+ SLT hours/week. Greatest clinical gains were associated with frequent SLT for overall language, functional communication (3-5+ days/week), and comprehension (4-5 days/week). Evidence of comprehension gains was absent for SLT <= 20 hours, <3 hours/week, and <= 3 days/week. Mixed receptive-expressive therapy, functionally tailored, with prescribed home practice was associated with the greatest overall gains. Relative variance was <30%. Risk of trial bias was low to moderate; low for meta-biases. CONCLUSIONS: Greatest language recovery was associated with frequent, functionally tailored, receptive-expressive SLT, with prescribed home practice at a greater intensity and duration than reports of usual clinical services internationally. These exploratory findings suggest critical therapeutic ranges, informing hypothesis-testing trials and tailoring of clinical services. Registration: URL: ; Unique identifier: CRD42018110947.
ISSN
0039-2499
URI
https://hdl.handle.net/10371/177982
DOI
https://doi.org/10.1161/STROKEAHA.121.035216
Files in This Item:
There are no files associated with this item.
Appears in Collections:

Altmetrics

Item View & Download Count

  • mendeley

Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.

Share